Eczema News and Research

Latest Eczema News and Research

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

The Journal of the American Academy of Dermatology (JAAD) has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses - 2.5% and 3.75% - administered daily on a 2-week treatment cycle. The study demonstrates that both formulations were superior to placebo, and that imiquimod 3.75% on a daily 2-week treatment cycle is superior to imiquimod 2.5% in treating actinic keratosis (AK) on a large surface area - the face or balding scalp.

9 Mar 2010

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

The Journal of the American Academy of Dermatology has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses – 2.5% and 3.75% – administered daily on either 2-week or 3-week treatment cycles.

9 Mar 2010

Scientists identify EoE-associated region in human chromosome

Scientists have identified a region of a human chromosome that is associated with eosinophilic esophagitis (EoE), a recently recognized allergic disease. People with EoE frequently have difficulty eating or may be allergic to one or more foods. This study further suggests that a suspected so-called master allergy gene may play a role in the development of this rare but debilitating disorder.

8 Mar 2010

Pediatrics researchers identify major gene location responsible for EoE

Pediatrics researchers have identified the first major gene location responsible for a severe, often painful type of food allergy called eosinophilic esophagitis (EoE). In this disease, which may cause weight loss, vomiting, heartburn and swallowing difficulties, a patient may be unable to eat a wide variety of foods.

7 Mar 2010

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.

5 Mar 2010

Step-up treatments may benefit children with asthma on low-dose inhaled corticosteroids

Children with asthma who continue to have symptoms while using low-dose inhaled corticosteroids could benefit from increasing the dosage or adding one of two asthma drugs, a new study by researchers at Washington University School of Medicine and other institutions finds.

3 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Study: LABA can be effective step-up treatment for children whose asthma is not well controlled

For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments. National Jewish clinician-scientists Stanley Szefler, Joseph Spahn, Ronina Covar Gary Larsen and Lynn Taussig, and colleagues in the NIH-funded Childhood Asthma Research and Education Network published their findings March 2, 2010, online in the New England Journal of Medicine.

3 Mar 2010

Dead Sea resorts introduce world-renowned treatment for people with dermatological diseases

The Dead Sea is the only place in the world that combines year-round hot weather, an oxygen-enriched atmosphere, therapeutic UVB solar radiation, a mineral-rich salt sea, world famous mineral-rich mud, thermo-mineral hot springs and luxurious spas.

3 Mar 2010

Eczema in early childhood may influence behavior and mental health later in life

Eczema in early childhood may influence behavior and mental health later in life. This is a key finding of a prospective birth cohort study to which scientists of Helmholtz Zentrum München contributed.

11 Feb 2010

Eczema can lead to behavioral and psychological problems in children

11 Feb 2010

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Glissandra Skincare™ Inc., dedicated to the research, development, and manufacturing of anti-aging skincare products, announced it has signed its first distributorship agreement granting Enchanted Meadow the rights to distribute Glissandra to its more than 2000 spa and gift industry retailers throughout the US and Canada.

10 Feb 2010

Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint

LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.

2 Feb 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

NTNU: 40% of two-year-olds report allergy-related disorders

Allergies and asthma are a continuing health problem in most developed countries, but just how do these ailments develop over the course of a childhood? In a population-based study designed to help answer this question, researchers at the Norwegian University of Science and Technology (NTNU) found that 40 per cent - or two of five -- of nearly 5,000 two-year-olds had at least one reported allergy-related disorder. The most common symptom was wheezing, which was reported in 26 per cent of all children in the study, says Ingeborg Smidesang, a PhD candidate in the university's Faculty of Medicine, and the primary author of the study.

25 Jan 2010

Study identifies new mechanism that causes allergic response in people

WHAT: A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema) and food allergy.

21 Jan 2010

LEO Pharma launches psoriasis franchise in the U.S.

Denmark-based LEO Pharma, a global leader in dermatology and critical care, announced its official launch in the U.S. Headquartered in Parsippany, New Jersey, LEO Pharma U.S. will be one of the largest individual operations in the pharmaceutical company’s network of worldwide affiliates and is expected to contribute significantly to the company revenues in 2010.

20 Jan 2010

freshHAIR: A new hair care line to prevent acne

Renee Cobos, MD, a board certified dermatologist and associate professor of dermatology at the University of California, Irvine, announced the launch of RC freshHAIR™, the first dermatologist-created hair care line that is specifically formulated to treat and prevent acne, acne rosacea, seborrhea (dandruff) and oily skin. RC freshHAIR is the newest addition to the RC Dermatology™ line of skin care products.

18 Jan 2010

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).

7 Jan 2010

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

Children of parents who refuse vaccines are nine times more likely to get chickenpox compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado's Institute for Health Research.

5 Jan 2010

Eczema News and Research

Latest Eczema News and Research

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

Scientists identify EoE-associated region in human chromosome

Pediatrics researchers identify major gene location responsible for EoE

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

Step-up treatments may benefit children with asthma on low-dose inhaled corticosteroids

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Study: LABA can be effective step-up treatment for children whose asthma is not well controlled

Dead Sea resorts introduce world-renowned treatment for people with dermatological diseases

Eczema in early childhood may influence behavior and mental health later in life

Eczema can lead to behavioral and psychological problems in children

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

NTNU: 40% of two-year-olds report allergy-related disorders

Study identifies new mechanism that causes allergic response in people

LEO Pharma launches psoriasis franchise in the U.S.

freshHAIR: A new hair care line to prevent acne

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eczema News and Research

Latest Eczema News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in